{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:54:54Z","timestamp":1789692894398,"version":"4.0.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022CZTZ87"],"award-info":[{"award-number":["2022CZTZ87"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["20227HRFPJ"],"award-info":[{"award-number":["20227HRFPJ"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fragile X Syndrome (FXS) is the most common inherited intellectual disability and a leading monogenic cause of autism spectrum disorder (ASD). As a synaptic disorder, FXS involves the loss of Fragile X messenger ribonucleoprotein 1 (FMRP), leading to abnormal dendrite development and immature dendritic spines. Serotonergic signaling, essential for neuronal development and circuit remodeling, has been implicated in ASD and related conditions, including FXS, raising the possibility that serotonergic modulation could ameliorate neurodevelopmental impairments. This study investigated the therapeutic potential of psilocybin, a serotonergic compound, in the validated\n                    <jats:italic>Fmr1-<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u0394<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>exon 8<\/jats:italic>\n                    rat model of FXS. Psilocybin microdosing rescued deficits in NOR. Importantly, its benefits on recognition memory persisted despite pretreatment with the 5HT2AR antagonist, volinanserin, or the 5HT1AR antagonist, WAY-100635, indicating that classical serotonergic receptor activation is not required. In contrast, pretreatment with the TrkB receptor antagonist, ANA-12, abolished psilocybin\u2019s effects, implicating BDNF\/TrkB signaling as essential. At the molecular level, psilocybin normalized mature BDNF (mBDNF), increased TrkB, and restored downstream AKT signaling in the prefrontal cortex of\n                    <jats:italic>Fmr1-<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u0394<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>exon 8<\/jats:italic>\n                    rats, pathways strongly linked to synaptic plasticity and cognitive function. These findings demonstrate that psilocybin rescues object recognition memory deficits in this rat model of FXS via BDNF\/TrkB-AKT signaling rather than serotonergic receptor mechanisms. By dissociating therapeutic effects from hallucinogenic pathways, our results highlight psilocybin microdosing as a promising therapeutic strategy for neurodevelopmental disorders such as FXS and ASD.\n                  <\/jats:p>","DOI":"10.1038\/s41386-026-02361-x","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:28:49Z","timestamp":1770971329000},"page":"1454-1463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF\/TrkB signaling pathway"],"prefix":"10.1038","volume":"51","author":[{"given":"Fabrizio","family":"Ascone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Buzzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8172-1384","authenticated-orcid":false,"given":"Francesca","family":"Mottarlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Di Trapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Miglioranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Feo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Hausman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminobu","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8045-3146","authenticated-orcid":false,"given":"Lucia","family":"Caffino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8814-7706","authenticated-orcid":false,"given":"Fabio","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-6045","authenticated-orcid":false,"given":"Viviana","family":"Trezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2361_CR1","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/ajmg.a.36511","volume":"164A","author":"J Hunter","year":"2014","unstructured":"Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of Fragile X syndrome: a systematic review and meta-analysis. Am J Med Genet Part A. 2014;164A:1648\u201358.","journal-title":"Am J Med Genet Part A"},{"key":"2361_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.neubiorev.2014.01.006","volume":"46","author":"T Maurin","year":"2014","unstructured":"Maurin T, Zongaro S, Bardoni B. Fragile X syndrome: from molecular pathology to therapy. Neurosci Biobehav Rev. 2014;46:242\u201355.","journal-title":"Neurosci Biobehav Rev"},{"key":"2361_CR3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.devcel.2008.04.003","volume":"14","author":"JB Dictenberg","year":"2008","unstructured":"Dictenberg JB, Swanger SA, Antar LN, Singer RH, Bassell GJ. A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to Fragile X syndrome. Dev cell. 2008;14:926\u201339.","journal-title":"Dev cell"},{"key":"2361_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.65","volume":"3","author":"RJ Hagerman","year":"2017","unstructured":"Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB Jr., Moine H, Kooy RF, et al. Fragile X syndrome. Nat Rev Dis Primers. 2017;3:17065.","journal-title":"Nat Rev Dis Primers"},{"key":"2361_CR5","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1542\/peds.2016-1159F","volume":"139","author":"WE Kaufmann","year":"2017","unstructured":"Kaufmann WE, Kidd SA, Andrews HF, Budimirovic DB, Esler A, Haas-Givler B, et al. Autism spectrum disorder in Fragile X syndrome: co-occurring conditions and current treatment. Pediatrics. 2017;139:S194\u2013S206.","journal-title":"Pediatrics"},{"key":"2361_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/ajmg.a.32848","volume":"149A","author":"RN Hernandez","year":"2009","unstructured":"Hernandez RN, Feinberg RL, Vaurio R, Passanante NM, Thompson RE, Kaufmann WE. Autism spectrum disorder in Fragile X syndrome: a longitudinal evaluation. Am J Med Genet Part A. 2009;149A:1125\u201337.","journal-title":"Am J Med Genet Part A"},{"key":"2361_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41392-022-01081-0","volume":"7","author":"CC Jiang","year":"2022","unstructured":"Jiang CC, Lin LS, Long S, Ke XY, Fukunaga K, Lu YM, et al. Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications. Signal Transduct Target Ther. 2022;7:229.","journal-title":"Signal Transduct Target Ther"},{"key":"2361_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5582\/irdr.2014.01027","volume":"3","author":"AC Hanson","year":"2014","unstructured":"Hanson AC, Hagerman RJ. Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable Rare Dis Res. 2014;3:110\u20137.","journal-title":"Intractable Rare Dis Res"},{"key":"2361_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neuroscience.2015.11.010","volume":"321","author":"CL Muller","year":"2016","unstructured":"Muller CL, Anacker AMJ, Veenstra-VanderWeele J. The serotonin system in autism spectrum disorder: from biomarker to animal models. Neuroscience. 2016;321:24\u201341.","journal-title":"Neuroscience"},{"key":"2361_CR10","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/sj.mp.4001167","volume":"7","author":"DC Chugani","year":"2002","unstructured":"Chugani DC. Role of altered brain serotonin mechanisms in autism. Mol Psychiatry. 2002;7:S16\u20137.","journal-title":"Mol Psychiatry"},{"key":"2361_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fnbeh.2015.00065","volume":"9","author":"L Costa","year":"2015","unstructured":"Costa L, Sardone LM, Lacivita E, Leopoldo M, Ciranna L. Novel agonists for serotonin 5-HT7 receptors reverse metabotropic glutamate receptor-mediated long-term depression in the hippocampus of wild-type and Fmr1 KO mice, a model of Fragile X Syndrome. Front Behav Neurosci. 2015;9:65.","journal-title":"Front Behav Neurosci"},{"key":"2361_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78:481\u201389.","journal-title":"JAMA Psychiatry"},{"key":"2361_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","volume":"181","author":"D Nutt","year":"2020","unstructured":"Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic psychiatry\u2019s brave new world. Cell. 2020;181:24\u201328.","journal-title":"Cell"},{"key":"2361_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s44184-023-00053-8","volume":"3","author":"KV Bhatt","year":"2024","unstructured":"Bhatt KV, Weissman CR. The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects. Npj Ment Health Res. 2024;3:7.","journal-title":"Npj Ment Health Res"},{"key":"2361_CR15","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"2361_CR16","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"Moliner R","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341.","journal-title":"Nat Neurosci"},{"key":"2361_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/dneu.20765","volume":"70","author":"A Yoshii","year":"2010","unstructured":"Yoshii A, Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol. 2010;70:304\u201322.","journal-title":"Dev Neurobiol"},{"key":"2361_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/dneu.20774","volume":"70","author":"S Cohen-Cory","year":"2010","unstructured":"Cohen-Cory S, Kidane AH, Shirkey NJ, Marshak S. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev Neurobiol. 2010;70:271\u201388.","journal-title":"Dev Neurobiol"},{"key":"2361_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.neuropharm.2013.05.018","volume":"76","author":"ML Castren","year":"2014","unstructured":"Castren ML, Castren E. BDNF in Fragile X syndrome. Neuropharmacology. 2014;76:729\u201336.","journal-title":"Neuropharmacology"},{"key":"2361_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00213-022-06286-3","volume":"240","author":"V Buzzelli","year":"2023","unstructured":"Buzzelli V, Carbone E, Manduca A, Schiavi S, Feo A, Perederiy JV, et al. Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome. Psychopharmacology. 2023;240:137\u201347.","journal-title":"Psychopharmacology"},{"key":"2361_CR21","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1093\/cercor\/bhz029","volume":"29","author":"CEM Golden","year":"2019","unstructured":"Golden CEM, Breen MS, Koro L, Sonar S, Niblo K, Browne A, et al. Deletion of the KH1 domain of Fmr1 Leads to transcriptional alterations and attentional deficits in rats. Cereb Cortex. 2019;29:2228\u201344.","journal-title":"Cereb Cortex"},{"key":"2361_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1037\/a0035988","volume":"128","author":"SM Hamilton","year":"2014","unstructured":"Hamilton SM, Green JR, Veeraragavan S, Yuva L, McCoy A, Wu Y, et al. Fmr1 and Nlgn3 knockout rats: novel tools for investigating autism spectrum disorders. Behav Neurosci. 2014;128:103\u20139.","journal-title":"Behav Neurosci"},{"key":"2361_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41386-022-01454-7","volume":"48","author":"S Schiavi","year":"2023","unstructured":"Schiavi S, Manduca A, Carbone E, Buzzelli V, Rava A, Feo A, et al. Anandamide and 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism based on FMR1 deletion in rats. Neuropsychopharmacology. 2023;48:897\u2013907.","journal-title":"Neuropsychopharmacology"},{"key":"2361_CR24","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897\u2013902.","journal-title":"Neuroreport"},{"key":"2361_CR25","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"LX Shao","year":"2021","unstructured":"Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535\u201344.e4.","journal-title":"Neuron"},{"key":"2361_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331.","journal-title":"J Basic Clin Pharm"},{"key":"2361_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106204","volume":"174","author":"OA Syed","year":"2025","unstructured":"Syed OA, Petranker R, Tsang B. The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field. Neurosci Biobehav Rev. 2025;174:106204.","journal-title":"Neurosci Biobehav Rev"},{"key":"2361_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1040217","volume":"13","author":"CA MacCallum","year":"2022","unstructured":"MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217.","journal-title":"Front Psychiatry"},{"key":"2361_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02039-0","volume":"12","author":"F Cavanna","year":"2022","unstructured":"Cavanna F, Muller S, de la Fuente LA, Zamberlan F, Palmucci M, Janeckova L, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry. 2022;12:307.","journal-title":"Transl Psychiatry"},{"key":"2361_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108178","volume":"215","author":"JT Madden","year":"2020","unstructured":"Madden JT, Reyna NC, Pentkowski NS. Antagonizing serotonin 2A (5-HT(2A)) receptors attenuates methamphetamine-induced reward and blocks methamphetamine-induced anxiety-like behaviors in adult male rats. Drug alcohol Depend. 2020;215:108178.","journal-title":"Drug alcohol Depend"},{"key":"2361_CR31","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00213-022-06092-x","volume":"239","author":"AM Jaster","year":"2022","unstructured":"Jaster AM, Elder H, Marsh SA, de la Fuente Revenga M, Negus SS, Gonzalez-Maeso J. Effects of the 5-HT(2A) receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents. Psychopharmacology. 2022;239:1665\u201377.","journal-title":"Psychopharmacology"},{"key":"2361_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.npp.1300024","volume":"28","author":"I Misane","year":"2003","unstructured":"Misane I, Ogren SO. Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology. 2003;28:253\u201364.","journal-title":"Neuropsychopharmacology"},{"key":"2361_CR33","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1172\/JCI43992","volume":"121","author":"M Cazorla","year":"2011","unstructured":"Cazorla M, Premont J, Mann A, Girard N, Kellendonk C, Rognan D. Identification of a low-molecular-weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Investig. 2011;121:1846\u201357.","journal-title":"J Clin Investig"},{"key":"2361_CR34","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1021\/acs.jmedchem.3c01225","volume":"67","author":"SA Raithatha","year":"2024","unstructured":"Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press D, Cook SG, et al. Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders. J Med Chem. 2024;67:1024\u201343.","journal-title":"J Med Chem"},{"key":"2361_CR35","doi-asserted-by":"publisher","first-page":"111234","DOI":"10.1016\/j.pnpbp.2024.111234","volume":"136","author":"A Rava","year":"2025","unstructured":"Rava A, Buzzelli V, Feo A, Ascone F, Di Trapano M, Schiavi S, et al. Role of peroxisome proliferator-activated receptors alpha and gamma in mediating the beneficial effects of beta-caryophyllene in a rat model of Fragile X syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111234.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2361_CR36","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3389\/fncel.2019.00479","volume":"13","author":"S Schiavi","year":"2019","unstructured":"Schiavi S, Iezzi D, Manduca A, Leone S, Melancia F, Carbone C, et al. Reward-related behavioral, neurochemical and electrophysiological changes in a rat model of autism based on prenatal exposure to valproic acid. Front Cell Neurosci. 2019;13:479.","journal-title":"Front Cell Neurosci"},{"key":"2361_CR37","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1523\/JNEUROSCI.2737-14.2015","volume":"35","author":"JM Gray","year":"2015","unstructured":"Gray JM, Vecchiarelli HA, Morena M, Lee TT, Hermanson DJ, Kim AB, et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J Neurosci. 2015;35:3879\u201392.","journal-title":"J Neurosci"},{"key":"2361_CR38","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1111\/bph.15211","volume":"177","author":"L Caffino","year":"2020","unstructured":"Caffino L, Verheij MMM, Roversi K, Targa G, Mottarlini F, Popik P, et al. Hypersensitivity to amphetamine\u2019s psychomotor and reinforcing effects in serotonin transporter knockout rats: glutamate in the nucleus accumbens. Br J Pharmacol. 2020;177:4532\u201347.","journal-title":"Br J Pharmacol"},{"key":"2361_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109767","volume":"242","author":"L Caffino","year":"2024","unstructured":"Caffino L, Mottarlini F, Piva A, Rizzi B, Fumagalli F, Chiamulera C. Temporal dynamics of BDNF signaling recruitment in the rat prefrontal cortex and hippocampus following a single infusion of a translational dose of ketamine. Neuropharmacology. 2024;242:109767.","journal-title":"Neuropharmacology"},{"key":"2361_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/jnr.21139","volume":"85","author":"T Aid","year":"2007","unstructured":"Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res. 2007;85:525\u201335.","journal-title":"J Neurosci Res"},{"key":"2361_CR41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.brs.2022.02.003","volume":"15","author":"AD Ramnauth","year":"2022","unstructured":"Ramnauth AD, Maynard KR, Kardian AS, Phan BN, Tippani M, Rajpurohit S, et al. Induction of Bdnf from promoter I following electroconvulsive seizures contributes to structural plasticity in neurons of the piriform cortex. Brain Stimul. 2022;15:427\u201333.","journal-title":"Brain Stimul"},{"key":"2361_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.mcn.2007.08.011","volume":"37","author":"C Chiaruttini","year":"2008","unstructured":"Chiaruttini C, Sonego M, Baj G, Simonato M, Tongiorgi E. BDNF mRNA splice variants display activity-dependent targeting to distinct hippocampal laminae. Mol Cell Neurosci. 2008;37:11\u20139.","journal-title":"Mol Cell Neurosci"},{"key":"2361_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.mcn.2004.11.010","volume":"28","author":"PP Pattabiraman","year":"2005","unstructured":"Pattabiraman PP, Tropea D, Chiaruttini C, Tongiorgi E, Cattaneo A, Domenici L. Neuronal activity regulates the developmental expression and subcellular localization of cortical BDNF mRNA isoforms in vivo. Mol Cell Neurosci. 2005;28:556\u201370.","journal-title":"Mol Cell Neurosci"},{"key":"2361_CR44","doi-asserted-by":"crossref","unstructured":"Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The Therapeutic Potential of Psilocybin. Molecules. 2021;26:2948.","DOI":"10.3390\/molecules26102948"},{"key":"2361_CR45","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","volume":"48","author":"GM Goodwin","year":"2023","unstructured":"Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, et al. Psilocybin for treatment-resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023;48:1492\u201399.","journal-title":"Neuropsychopharmacology"},{"key":"2361_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022;36:151\u201358.","journal-title":"J Psychopharmacol"},{"key":"2361_CR47","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol"},{"key":"2361_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.749068","volume":"12","author":"A Markopoulos","year":"2021","unstructured":"Markopoulos A, Inserra A, De Gregorio D, Gobbi G. Evaluating the potential use of serotonergic psychedelics in autism spectrum disorder. Front Pharmacol. 2021;12:749068.","journal-title":"Front Pharmacol"},{"key":"2361_CR49","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1021\/acsptsci.5c00034","volume":"8","author":"X Wang","year":"2025","unstructured":"Wang X, Lin C. Psychedelics and pro-social behaviors: a perspective on autism spectrum disorders. ACS Pharmacol Transl Sci. 2025;8:903\u201306.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2361_CR50","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","volume":"11","author":"M Hibicke","year":"2020","unstructured":"Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but not Ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci. 2020;11:864\u201371.","journal-title":"ACS Chem Neurosci"},{"key":"2361_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117415","volume":"320","author":"A Hern\u00e1ndez-Le\u00f3n","year":"2024","unstructured":"Hern\u00e1ndez-Le\u00f3n A, Escamilla-Orozco RI, Tabal-Robles AR, Mart\u00ednez-Vargas D, Romero-Bautista L, Escamilla-Soto G, et al. Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice. J Ethnopharmacol. 2024;320:117415.","journal-title":"J Ethnopharmacol"},{"key":"2361_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-03383-z","volume":"15","author":"Z Wang","year":"2025","unstructured":"Wang Z, Robbins B, Zhuang R, van Bruggen R, Sandini T, Li XM, et al. Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using Wistar Kyoto rats. Sci Rep. 2025;15:18432.","journal-title":"Sci Rep"},{"key":"2361_CR53","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41586-023-06204-3","volume":"618","author":"R Nardou","year":"2023","unstructured":"Nardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, de Deus JL, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;618:790\u201398.","journal-title":"Nature"},{"key":"2361_CR54","unstructured":"Orsini AP. Autism on Acid: How LSD Helped Me Understand, Navigate, Alter & Appreciate My Autistic Perceptions. https:\/\/books.google.co.in\/books?id=CCq5zgEACAAJ."},{"key":"2361_CR55","doi-asserted-by":"crossref","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci USA. 2021;118:e2022489118.","DOI":"10.1073\/pnas.2022489118"},{"key":"2361_CR56","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700\u201306.","journal-title":"Science"},{"key":"2361_CR57","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4:568\u201372.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2361_CR58","doi-asserted-by":"publisher","first-page":"111347","DOI":"10.1016\/j.pnpbp.2025.111347","volume":"138","author":"A Bysiek","year":"2025","unstructured":"Bysiek A, Wojtas A, Szpregiel I, Wawrzczak-Bargiela A, Mackowiak M, Golembiowska K. The effect of low-dose psilocybin on brain neurotransmission and rat behavior. Prog Neuro Psychopharmacol Biol Psychiatry. 2025;138:111347.","journal-title":"Prog Neuro Psychopharmacol Biol Psychiatry"},{"key":"2361_CR59","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48:104\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"2361_CR60","doi-asserted-by":"crossref","unstructured":"Ilchibaeva T, Tsybko A, Zeug A, Muller FE, Guseva D, Bischoff S, et al. Serotonin receptor 5-HT(2A) regulates trkB receptor function in heteroreceptor complexes. Cells. 2022;11:2384.","DOI":"10.3390\/cells11152384"},{"key":"2361_CR61","doi-asserted-by":"publisher","first-page":"16813","DOI":"10.1073\/pnas.1014168108","volume":"108","author":"G Baj","year":"2011","unstructured":"Baj G, Leone E, Chao MV, Tongiorgi E. Spatial segregation of BDNF transcripts enables BDNF to differentially shape distinct dendritic compartments. Proc Natl Acad Sci USA. 2011;108:16813\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2361_CR62","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/hipo.23600","volume":"34","author":"SV Bach","year":"2024","unstructured":"Bach SV, Bauman AJ, Hosein D, Tuscher JJ, Ianov L, Greathouse KM, et al. Distinct roles of Bdnf I and Bdnf IV transcript variant expression in hippocampal neurons. Hippocampus. 2024;34:218\u201329.","journal-title":"Hippocampus"},{"key":"2361_CR63","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41386-021-01132-0","volume":"47","author":"NP Friedman","year":"2022","unstructured":"Friedman NP, Robbins TW. The role of the prefrontal cortex in cognitive control and executive function. Neuropsychopharmacology. 2022;47:72\u201389.","journal-title":"Neuropsychopharmacology"},{"key":"2361_CR64","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrn.2017.74","volume":"18","author":"H Eichenbaum","year":"2017","unstructured":"Eichenbaum H. Prefrontal-hippocampal interactions in episodic memory. Nat Rev Neurosci. 2017;18:547\u201358.","journal-title":"Nat Rev Neurosci"},{"key":"2361_CR65","doi-asserted-by":"publisher","first-page":"17269","DOI":"10.1523\/JNEUROSCI.4095-11.2011","volume":"31","author":"CA Orsini","year":"2011","unstructured":"Orsini CA, Kim JH, Knapska E, Maren S. Hippocampal and prefrontal projections to the basal amygdala mediate contextual regulation of fear after extinction. J Neurosci. 2011;31:17269\u201377.","journal-title":"J Neurosci"},{"key":"2361_CR66","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0166-4328(01)00367-9","volume":"127","author":"DG Mumby","year":"2001","unstructured":"Mumby DG. Perspectives on object-recognition memory following hippocampal damage: lessons from studies in rats. Behav Brain Res. 2001;127:159\u201381.","journal-title":"Behav Brain Res"},{"key":"2361_CR67","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bbr.2015.06.030","volume":"292","author":"JF Morici","year":"2015","unstructured":"Morici JF, Bekinschtein P, Weisstaub NV. Medial prefrontal cortex role in recognition memory in rodents. Behav Brain Res. 2015;292:241\u201351.","journal-title":"Behav Brain Res"},{"key":"2361_CR68","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1017\/S1461145711000150","volume":"15","author":"F Fumagalli","year":"2012","unstructured":"Fumagalli F, Calabrese F, Luoni A, Bolis F, Racagni G, Riva MA. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal conditions and in response to acute stress. Int J Neuropsychopharmacol. 2012;15:235\u201346.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2361_CR69","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41386-023-01717-x","volume":"49","author":"J Kim","year":"2024","unstructured":"Kim J, He MJ, Widmann AK, Lee FS. The role of neurotrophic factors in novel, rapid psychiatric treatments. Neuropsychopharmacology. 2024;49:227\u201345.","journal-title":"Neuropsychopharmacology"},{"key":"2361_CR70","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12031-014-0257-z","volume":"54","author":"T Kovacs","year":"2014","unstructured":"Kovacs T, Bansagi B, Kelemen O, Keri S. Neuregulin 1-induced AKT and ERK phosphorylation in patients with Fragile X syndrome (FXS) and intellectual disability associated with obstetric complications. J Mol Neurosci. 2014;54:119\u201324.","journal-title":"J Mol Neurosci"},{"key":"2361_CR71","doi-asserted-by":"publisher","first-page":"111036","DOI":"10.1016\/j.pnpbp.2024.111036","volume":"134","author":"B Zhang","year":"2024","unstructured":"Zhang B, Zhang J, Chen H, Qiao D, Guo F, Hu X, et al. Role of FMRP in AKT\/mTOR pathway-mediated hippocampal autophagy in Fragile X syndrome. Prog Neuro Psychopharmacol Biol Psychiatry. 2024;134:111036.","journal-title":"Prog Neuro Psychopharmacol Biol Psychiatry"},{"key":"2361_CR72","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1523\/JNEUROSCI.3696-09.2010","volume":"30","author":"A Sharma","year":"2010","unstructured":"Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, et al. Dysregulation of mTOR signaling in Fragile X syndrome. J Neurosci. 2010;30:694\u2013702.","journal-title":"J Neurosci"},{"key":"2361_CR73","doi-asserted-by":"publisher","first-page":"7847","DOI":"10.1523\/JNEUROSCI.1496-08.2008","volume":"28","author":"H Hu","year":"2008","unstructured":"Hu H, Qin Y, Bochorishvili G, Zhu Y, van Aelst L, Zhu JJ. Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with Fragile X syndrome. J Neurosci. 2008;28:7847\u201362.","journal-title":"J Neurosci"},{"key":"2361_CR74","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.nbd.2010.10.018","volume":"41","author":"V Louhivuori","year":"2011","unstructured":"Louhivuori V, Vicario A, Uutela M, Rantamaki T, Louhivuori LM, Castren E, et al. BDNF and TrkB in neuronal differentiation of Fmr1-knockout mouse. Neurobiol Dis. 2011;41:469\u201380.","journal-title":"Neurobiol Dis"},{"key":"2361_CR75","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s12035-023-03226-w","volume":"60","author":"YS Chen","year":"2023","unstructured":"Chen YS, Zhang SM, Tan W, Zhu Q, Yue CX, Xiang P, et al. Early 7,8-Dihydroxyflavone administration ameliorates synaptic and behavioral deficits in the young fxs animal model by acting on BDNF-trkB pathway. Mol Neurobiol. 2023;60:2539\u201352.","journal-title":"Mol Neurobiol"},{"key":"2361_CR76","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.bcp.2009.09.023","volume":"79","author":"CJ Yuskaitis","year":"2010","unstructured":"Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of Fragile X syndrome. Biochem Pharmacol. 2010;79:632\u201346.","journal-title":"Biochem Pharmacol"},{"key":"2361_CR77","doi-asserted-by":"crossref","unstructured":"You H, Lu B. Diverse Functions of Multiple Bdnf Transcripts Driven by Distinct Bdnf Promoters. Biomolecules. 2023;13:655.","DOI":"10.3390\/biom13040655"},{"key":"2361_CR78","doi-asserted-by":"crossref","unstructured":"Park D, Lee G, Lee WG, Kim B, Lee Y, Kim JW. The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine. Mol Psychiatry. 2025;30:4910\u201327.","DOI":"10.1038\/s41380-025-03100-2"},{"key":"2361_CR79","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.phrs.2015.12.014","volume":"104","author":"L Caffino","year":"2016","unstructured":"Caffino L, Di Chio M, Giannotti G, Venniro M, Mutti A, Padovani L, et al. The modulation of BDNF expression and signalling dissects the antidepressant from the reinforcing properties of ketamine: Effects of single infusion vs. chronic self-administration in rats. Pharmacol Res. 2016;104:22\u201330.","journal-title":"Pharmacol Res"},{"key":"2361_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.889636","volume":"13","author":"A Napolitano","year":"2022","unstructured":"Napolitano A, Schiavi S, La Rosa P, Rossi-Espagnet MC, Petrillo S, Bottino F, et al. Sex differences in autism spectrum disorder: diagnostic, neurobiological, and behavioral features. Front psychiatry. 2022;13:889636.","journal-title":"Front psychiatry"},{"key":"2361_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.800","volume":"7","author":"SO Nolan","year":"2017","unstructured":"Nolan SO, Reynolds CD, Smith GD, Holley AJ, Escobar B, Chandler MA, et al. Deletion of Fmr1 results in sex-specific changes in behavior. Brain Behav. 2017;7:e00800.","journal-title":"Brain Behav"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02361-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:21:30Z","timestamp":1782206490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02361-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1038\/s41386-026-02361-x","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Marvin Hausman previously served as Scientific Director at NOVA MENTIS Life Science Corp., which partially funded this study and provided the psilocybin used. All authors, including Dr. Hausman, declare that they have no current or prior financial, commercial, or advisory relationships with NOVA MENTIS Life Science Corp. beyond the contributions described above. NOVA MENTIS Life Science Corp. has since undergone corporate restructuring and has ceased its research operations. The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}